{"id":275,"date":"2026-07-29T14:53:47","date_gmt":"2026-07-29T12:53:47","guid":{"rendered":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/"},"modified":"2026-07-29T14:54:04","modified_gmt":"2026-07-29T12:54:04","slug":"real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/","title":{"rendered":"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>Real-world evidence (RWE) has moved from the margins of EU medicines regulation to its core. Through initiatives such as DARWIN EU, the European Medicines Agency now routinely commissions real-world studies to support decisions across a product&#8217;s lifecycle &mdash; and sponsors who understand how regulators use this evidence are better placed to strengthen their own submissions.<\/strong><\/p>\n\n<h2>What counts as real-world evidence<\/h2>\n<p>RWE is clinical evidence derived from real-world data: information collected outside conventional randomised controlled trials. Sources include electronic health records, disease and product registries, claims databases and pharmacy records. RWE complements rather than replaces the randomised trial &mdash; it answers questions about how a medicine performs in routine practice, in populations often excluded from pivotal studies.<\/p>\n\n<h2>DARWIN EU and the EMA framework<\/h2>\n<p>DARWIN EU (Data Analytics and Real World Interrogation Network) is a federated network of European real-world data sources coordinated by the EMA. It allows regulators to request analyses across large patient populations without centralising the underlying data. The network has expanded rapidly and now draws on data covering hundreds of millions of patients, running a growing number of studies each year to answer questions posed by EU regulators.<\/p>\n<p>The EMA&#8217;s framework describes how RWE supports regulatory decision-making across the lifecycle:<\/p>\n<ul>\n<li>characterising diseases and treatment patterns to inform development;<\/li>\n<li>supporting or contextualising evidence in a marketing authorisation application;<\/li>\n<li>monitoring safety and effectiveness after approval, including for conditional or exceptional approvals.<\/li>\n<\/ul>\n\n<h2>Where RWE adds regulatory value<\/h2>\n<ul>\n<li>Rare diseases and small populations, where randomised trials are difficult or unethical to power.<\/li>\n<li>Post-authorisation safety and efficacy studies requested as conditions of approval.<\/li>\n<li>Single-arm trials that require an external comparator drawn from real-world data.<\/li>\n<li>Pharmacovigilance signal evaluation and benefit-risk reassessment.<\/li>\n<\/ul>\n\n<h2>Getting RWE accepted<\/h2>\n<p>Regulators judge RWE on the quality of the data and the rigour of the method, not the volume of records. A study is only as credible as its protocol. Fitness-for-purpose of the data source, a pre-specified analysis plan, transparent handling of confounding and missing data, and reproducibility all determine whether a regulator will rely on the result. Engaging early through scientific advice is the single most reliable way to establish whether a proposed real-world study will be accepted.<\/p>\n\n<h2>How PQRA helps<\/h2>\n<p>PQRA helps sponsors design and position real-world evidence so that it withstands regulatory scrutiny. We advise on fit-for-purpose data sources, protocol and analysis-plan design, alignment with EMA expectations and post-authorisation study commitments, and the integration of RWE into both regulatory submissions and market-access dossiers, where the same evidence increasingly supports health technology assessment.<\/p>\n<p><a href=\"\/el\/contact\/\">Talk to PQRA<\/a> about building real-world evidence into your regulatory strategy.<\/p>","protected":false},"excerpt":{"rendered":"<p>Real-world evidence (RWE) has moved from the margins of EU medicines regulation to its core. Through initiatives such as DARWIN EU, the European Medicines Agency now routinely commissions real-world studies to support decisions across a product&#8217;s lifecycle &mdash; and sponsors who understand how regulators use this evidence are better placed to strengthen their own submissions. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":276,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_kadence_starter_templates_imported_post":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core - PQRA\" \/>\n<meta property=\"og:description\" content=\"Real-world evidence (RWE) has moved from the margins of EU medicines regulation to its core. Through initiatives such as DARWIN EU, the European Medicines Agency now routinely commissions real-world studies to support decisions across a product&#8217;s lifecycle &mdash; and sponsors who understand how regulators use this evidence are better placed to strengthen their own submissions. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T12:53:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-29T12:54:04+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core\",\"datePublished\":\"2026-07-29T12:53:47+00:00\",\"dateModified\":\"2026-07-29T12:54:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/rwe-eu.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/\",\"name\":\"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/rwe-eu.png\",\"datePublished\":\"2026-07-29T12:53:47+00:00\",\"dateModified\":\"2026-07-29T12:54:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/rwe-eu.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/rwe-eu.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"],\"url\":\"https:\\\/\\\/www.pqra.gr\\\/el\\\/author\\\/dgkikas_rwvrose8\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/","og_locale":"el_GR","og_type":"article","og_title":"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core - PQRA","og_description":"Real-world evidence (RWE) has moved from the margins of EU medicines regulation to its core. Through initiatives such as DARWIN EU, the European Medicines Agency now routinely commissions real-world studies to support decisions across a product&#8217;s lifecycle &mdash; and sponsors who understand how regulators use this evidence are better placed to strengthen their own submissions. [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/","og_site_name":"PQRA","article_published_time":"2026-07-29T12:53:47+00:00","article_modified_time":"2026-07-29T12:54:04+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"2 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core","datePublished":"2026-07-29T12:53:47+00:00","dateModified":"2026-07-29T12:54:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/rwe-eu.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/","url":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/","name":"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/rwe-eu.png","datePublished":"2026-07-29T12:53:47+00:00","dateModified":"2026-07-29T12:54:04+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/rwe-eu.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/rwe-eu.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/real-world-evidence-in-eu-medicines-regulation-from-nice-to-have-to-core\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"Real-World Evidence in EU Medicines Regulation: From Nice-to-Have to Core"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"],"url":"https:\/\/www.pqra.gr\/el\/author\/dgkikas_rwvrose8\/"}]}},"jetpack_featured_media_url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/rwe-eu.png","_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=275"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/275\/revisions"}],"predecessor-version":[{"id":277,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/275\/revisions\/277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/276"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}